Utility of T315I mutation in Egyptian patients with chronic myeloid leukemia

References

• Zhang J, Jin Y, Pan J. Inhibitory effect of the anthelmintic drug pyrvinium pamoate on T315I BCRABLpositive CML cells. Mol Med Rep. 2017;16(6):9217–9223. doi: 10.3892/mmr.2017.7685
   PubMed Web of Science ®Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2):76–94. doi: 10.1159/000046636
   PubMed Web of Science ®Google Scholar
• Ning L, Hu C, Lu P, et al. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol. 2020;9(1):1–4. doi: 10.1186/s40164-020-00185-z
   PubMed Web of Science ®Google Scholar
• Khorshied MM, Shaheen IA, Khalil RE, et al. Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in chronic myeloid leukemia: an Egyptian study. Med Oncol. 2014;31(1):794. doi: 10.1007/s12032-013-0794-2
   PubMed Web of Science ®Google Scholar
• Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530–42. doi: 10.1016/j.ccell.2020.03.006
   PubMed Web of Science ®Google Scholar
• Dhahi MA, Matti BF, Fadel S. Molecular screening for T315I and F317L resistance mutations in Iraqi chronic myeloid leukemia non-responders patients to imatinib. Cancer Clin Oncol. 2013;2(2):55–61. doi: 10.5539/cco.v2n2p55
   Google Scholar
• Lussana F, Intermesoli T, Stefanoni P, et al. Mechanisms of resistance to targeted therapies in chronic myeloid leukemia. Mechanisms of drug resistance in cancer therapy. Handb Exp Pharmacol. 2018;249:231–250.
   PubMedGoogle Scholar
• Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res. 2006;12(24):7374–9. doi: 10.1158/1078-0432.CCR-06-1516
   PubMed Web of Science ®Google Scholar
• Sampaio MM, Santos ML, Marques HS, et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review. World J Clin Oncol. 2021;12(2):69. doi: 10.5306/wjco.v12.i2.69
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100(3):1014–8. doi: 10.1182/blood.V100.3.1014
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in“good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–799. doi: 10.1182/blood.V63.4.789.789
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998;90(11):850–9. doi: 10.1093/jnci/90.11.850
   PubMedGoogle Scholar
• Iqbal Z, Aleem A, Iqbal M, et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PloS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717
   PubMed Web of Science ®Google Scholar
• Liu J, Yang H, Xu X, et al. Mutations in the BCRABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis. Oncol Lett. 2020;20(2):1071–1076. doi: 10.3892/ol.2020.11650
   PubMed Web of Science ®Google Scholar
• Chahardouli B, Zaker F, Mousavi SA, et al. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematology. 2013;18(3):158–62. doi: 10.1179/1607845412Y.0000000050
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106(6):2128–37. doi: 10.1182/blood-2005-03-1036
   PubMed Web of Science ®Google Scholar
• El-Menoufy MA, El Naggar AA, Ziada LE. ‘Gatekeeper’ mutation in patients with chronic myeloid leukemia resistant to imatinib therapy: effect on survival. Egypt J Haematol. 2018;43(3):138. doi: 10.4103/ejh.ejh_18_18
   Google Scholar
• Rejali L, Poopak B, Hasanzad M, et al. Characterizing of four common BCR-ABL kinase domain mutations (T315I, Y253H, M351T and E255K) in Iranian chronic myelogenous leukemia patients with imatinib resistance. Iran J Cancer Prev. 2015;8(3). doi: 10.17795/ijcp2334
   PubMedGoogle Scholar
• Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, et al. Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India. Ecancermedicalscience. 2016;10. doi: 10.3332/ecancer.2016.679
   PubMedGoogle Scholar
• Nicolini FE, Ibrahim AR, Soverini S, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98(10):1510. doi: 10.3324/haematol.2012.080234
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Of Hematol. 2016;91(2):252–265. doi: 10.1002/ajh.24275
   PubMed Web of Science ®Google Scholar